{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:00:27Z","timestamp":1790704827438,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.ijid.2023.05.017","type":"journal-article","created":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T01:02:33Z","timestamp":1684544553000},"page":"53-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Comparing recombinant human rabies monoclonal antibody (ormutivimab) with human rabies immunoglobulin (HRIG) for postexposure prophylaxis: A phase III, randomized, double-blind, non-inferiority trial"],"prefix":"10.1016","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6150-2296","authenticated-orcid":false,"given":"Xiaoqiang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8987-5836","authenticated-orcid":false,"given":"Yufeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangshu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaling","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cha","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingke","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingshuang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hancheng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1766-6442","authenticated-orcid":false,"given":"Xiaona","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2023.05.017_bib0001","article-title":"Estimating the global burden of endemic canine rabies","volume":"9","author":"Hampson","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijid.2023.05.017_bib0002","first-page":"360","article-title":"Re-evaluating the burden of rabies in Africa and Asia","volume":"83","author":"Knobel","year":"2005","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.ijid.2023.05.017_bib0003","doi-asserted-by":"crossref","unstructured":"World Health Organization. Rabies vaccines: WHO position paper \u2013 April 2018, https:\/\/www.who.int\/publications\/i\/item\/who-wer9316; 2018 [accessed 22 October 2022].","DOI":"10.1016\/j.vaccine.2018.06.061"},{"key":"10.1016\/j.ijid.2023.05.017_bib0004","unstructured":"SAGE Working Group on rabies vaccines and immunoglobulins and World Health Organization (WHO) Secretariat. Background paper: Proposed revision of the policy on rabies vaccines and rabies immunoglobulins, https:\/\/www.nitag-resource.org\/sites\/default\/files\/0cd83c26cce042fc02a514aa7c31e9616f281f46_1.pdf; 2017 [accessed 22 October 2022]."},{"key":"10.1016\/j.ijid.2023.05.017_bib0005","doi-asserted-by":"crossref","first-page":"5822","DOI":"10.1016\/j.vaccine.2021.08.066","article-title":"Rabies virus neutralizing activity, pharmacokinetics, and safety of the monoclonal antibody mixture SYN023 in combination with rabies vaccination: results of a phase 2, randomized, blinded, controlled trial","volume":"39","author":"McClain","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2023.05.017_bib0006","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/s41467-020-14398-7","article-title":"Structure of the prefusion-locking broadly neutralizing antibody RVC20 bound to the rabies virus glycoprotein","volume":"11","author":"Hellert","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijid.2023.05.017_bib0007","article-title":"A broad-spectrum and highly potent human monoclonal antibody cocktail for rabies prophylaxis","volume":"16","author":"Kim","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2023.05.017_bib0008","first-page":"399","article-title":"Development of recombinant human monoclonal antibody cocktail for post-exposure rabies prophylaxis","volume":"32","author":"Sun","year":"2016","journal-title":"Bing Du Xue Bao"},{"key":"10.1016\/j.ijid.2023.05.017_bib0009","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/cid\/cix791","article-title":"Comparison of a novel human rabies monoclonal antibody to human rabies immunoglobulin for postexposure prophylaxis: a phase 2\/3, randomized, single-blind, noninferiority, controlled study","volume":"66","author":"Gogtay","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2023.05.017_bib0010","doi-asserted-by":"crossref","first-page":"e2722","DOI":"10.1093\/cid\/ciaa779","article-title":"A phase 3, randomized, open-label, noninferiority trial evaluating anti-rabies monoclonal antibody cocktail (TwinrabTM) against human rabies immunoglobulin (HRIG)","volume":"73","author":"Kansagra","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2023.05.017_bib0011","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2026713","article-title":"Advances in the progress of monoclonal antibodies for rabies","volume":"18","author":"Fan","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.ijid.2023.05.017_bib0012","first-page":"256","article-title":"Study on neutralizing potency to different rabies virus strains of the recombinant human anti-rabies virus McAbs SO57 and SOJB","volume":"22","author":"Jia","year":"2006","journal-title":"Chin J Virol"},{"key":"10.1016\/j.ijid.2023.05.017_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2022.102267","article-title":"Efficacy of ormutivimab, a novel recombinant human anti-rabies monoclonal antibody, in post-exposure prophylaxis animal models","volume":"46","author":"Zhai","year":"2022","journal-title":"Travel Med Infect Dis"},{"key":"10.1016\/j.ijid.2023.05.017_bib0014","doi-asserted-by":"crossref","first-page":"6153","DOI":"10.1016\/j.vaccine.2022.09.022","article-title":"Neutralizing antibody activity, safety and immunogenicity of human anti-rabies virus monoclonal antibody (Ormutivimab) in Chinese healthy adults: a phase \u2161b randomized, double-blind, parallel-controlled study","volume":"40","author":"Li","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2023.05.017_bib0015","first-page":"986","article-title":"Safety of a single injection with recombinant human rabies immunoglobin at various dosages in humans","volume":"26","author":"Mei-Xia","year":"2013","journal-title":"Chin J Biol"},{"key":"10.1016\/j.ijid.2023.05.017_bib0016","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3390\/vaccines10081218","article-title":"Population pharmacodynamic analyses of human anti-rabies virus monoclonal antibody (ormutivimab) in healthy adult subjects","volume":"10","author":"Zhang","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ijid.2023.05.017_bib0017","first-page":"782","article-title":"Rabies virus neutralizing activity, safety, and immunogenicity of recombinant human rabies antibody compared with human rabies immunoglobulin in healthy adults","volume":"35","author":"Zhang","year":"2022","journal-title":"Biomed Environ Sci"},{"key":"10.1016\/j.ijid.2023.05.017_sbref0018","series-title":"Guidelines for adverse reaction classification standards for clinical trials of preventive vaccines","year":"2019"},{"key":"10.1016\/j.ijid.2023.05.017_bib0019","unstructured":"World Health Organization, Rupprecht CE, Fooks AR, Abela-Ridder B. Laboratory techniques in rabies, https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/310836\/9789241515153-eng.pdf; 2018 [accessed 22 October 2022]."},{"key":"10.1016\/j.ijid.2023.05.017_bib0020","unstructured":"Food and Drug Administration. Rabies: developing monoclonal antibody cocktails for the passive immunization component of post-exposure prophylaxis guidance for industry (draft guidance for industry), https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/rabies-developing-monoclonal-antibody-cocktails-passive-immunization-component-post-exposure; 2021 [accessed 22 October 2022]."},{"key":"10.1016\/j.ijid.2023.05.017_bib0021","first-page":"4","article-title":"Key points of clinical trial design of anti-rabies virus monoclonal antibodies","volume":"29","author":"Lin","year":"2020","journal-title":"Chin J New Drugs"},{"key":"10.1016\/j.ijid.2023.05.017_sbref0022","series-title":"Rabies vaccines: WHO position paper","year":"2010"},{"key":"10.1016\/j.ijid.2023.05.017_bib0023","unstructured":"World Health Organization. WHO expert consultation on rabies: second report, https:\/\/apps.who.int\/iris\/handle\/10665\/85346; 2005 [accessed 22 October 2022]."},{"key":"10.1016\/j.ijid.2023.05.017_bib0024","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1016\/j.vaccine.2010.03.039","article-title":"The immune response to rabies virus infection and vaccination","volume":"28","author":"Johnson","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2023.05.017_bib0025","unstructured":"World Health Organization. WHO Expert Committee on Rabies [meeting held in Geneva from 24 to 30 September 1991]: eighth report, http:\/\/apps.who.int\/iris\/handle\/10665\/39308; 1992 [accessed 22 October 2022]."},{"key":"10.1016\/j.ijid.2023.05.017_bib0026","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1080\/21645515.2015.1085142","article-title":"Local infiltration of rabies immunoglobulins without systemic intramuscular administration: an alternative cost effective approach for passive immunization against rabies","volume":"12","author":"Bharti","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.ijid.2023.05.017_bib0027","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1080\/21645515.2016.1255834","article-title":"Injecting rabies immunoglobulin (RIG) into wounds only: a significant saving of lives and costly RIG","volume":"13","author":"Bharti","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.ijid.2023.05.017_bib0028","doi-asserted-by":"crossref","first-page":"7141","DOI":"10.1016\/j.vaccine.2009.09.029","article-title":"Evidence for a 4-dose vaccine schedule for human rabies post-exposure prophylaxis in previously non-vaccinated individuals","volume":"27","author":"Rupprecht","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2023.05.017_bib0029","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1006\/biol.1998.0156","article-title":"Immunogenicity and safety in adults of a new chromatographically purified Vero-cell rabies vaccine (CPRV): a randomized, double-blind trial with purified Vero-cell rabies vaccine (PVRV)","volume":"26","author":"Lang","year":"1998","journal-title":"Biologicals"},{"key":"10.1016\/j.ijid.2023.05.017_bib0030","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0001-706X(99)00092-3","article-title":"Immunogenicity and effectiveness of post-exposure rabies prophylaxis with a new chromatographically purified Vero-cell rabies vaccine (CPRV): a two-stage randomised clinical trial in the Philippines","volume":"75","author":"Quiambao","year":"2000","journal-title":"Acta Trop"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971223005696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971223005696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T05:33:05Z","timestamp":1716010385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971223005696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":30,"alternative-id":["S1201971223005696"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2023.05.017","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing recombinant human rabies monoclonal antibody (ormutivimab) with human rabies immunoglobulin (HRIG) for postexposure prophylaxis: A phase III, randomized, double-blind, non-inferiority trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2023.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}